Plain-English translation of NCT06493370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether intravenous ascorbic acid (vitamin C) combined with gemcitabine and carboplatin chemotherapy can improve outcomes for people with muscle-invasive bladder cancer. You would receive two cycles of the chemotherapy drugs along with daily vitamin C infusions over 28 days, then proceed to surgery to remove your bladder. The researchers believe this medication combination may help shrink the cancer and improve your quality of life.
Many patients with muscle-invasive bladder cancer cannot safely receive the standard first-line chemotherapy drug cisplatin because of other health conditions or side effects. This trial is exploring whether adding this treatment can offer these patients a more effective and affordable option.
You likely qualify if…
You likely don't qualify if…
You would receive two cycles of chemotherapy (gemcitabine and carboplatin) given intravenously, along with daily vitamin C infusions administered over 28 days. After completing these two cycles, you would proceed to surgery to remove your bladder as planned. Throughout your participation, you would have regular visits for blood tests and monitoring, and you would be asked to contribute samples to a research biorepository to help advance bladder cancer research.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States